Michael F Miller, MD | |
3400 Delta Fair Blvd, Antioch, CA 94509-4004 | |
(925) 779-5000 | |
Not Available |
Full Name | Michael F Miller |
---|---|
Gender | Male |
Speciality | Allergy/immunology |
Experience | 48 Years |
Location | 3400 Delta Fair Blvd, Antioch, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437201662 | NPI | - | NPPES |
00G364110 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | G36411 (California) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Area-wide traffic calming schemes that discourage through-traffic from using residential roads are effective at reducing traffic-related injuries in high-income countries and may even reduce deaths. However, more research needs to be carried out to see whether these interventions will work in low- and middle-income countries, according to a Cochrane Systematic Review of the available evidence.
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.
A simple eye tracking test could hold the key to earlier Alzheimer's diagnosis, according to new research published today in the Journal of the American Aging Association.
An accurate, non-invasive, and low-cost method of testing for COVID-19 using samples taken from the screens of mobile phones has been developed by a team led by UCL researchers at Diagnosis Biotech.
› Verified 9 days ago
Entity Name | Permanente Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Area-wide traffic calming schemes that discourage through-traffic from using residential roads are effective at reducing traffic-related injuries in high-income countries and may even reduce deaths. However, more research needs to be carried out to see whether these interventions will work in low- and middle-income countries, according to a Cochrane Systematic Review of the available evidence.
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.
A simple eye tracking test could hold the key to earlier Alzheimer's diagnosis, according to new research published today in the Journal of the American Aging Association.
An accurate, non-invasive, and low-cost method of testing for COVID-19 using samples taken from the screens of mobile phones has been developed by a team led by UCL researchers at Diagnosis Biotech.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Michael F Miller, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Michael F Miller, MD 3400 Delta Fair Blvd, Antioch, CA 94509-4004 Ph: (925) 779-5000 |
News Archive
Area-wide traffic calming schemes that discourage through-traffic from using residential roads are effective at reducing traffic-related injuries in high-income countries and may even reduce deaths. However, more research needs to be carried out to see whether these interventions will work in low- and middle-income countries, according to a Cochrane Systematic Review of the available evidence.
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.
A simple eye tracking test could hold the key to earlier Alzheimer's diagnosis, according to new research published today in the Journal of the American Aging Association.
An accurate, non-invasive, and low-cost method of testing for COVID-19 using samples taken from the screens of mobile phones has been developed by a team led by UCL researchers at Diagnosis Biotech.
› Verified 9 days ago